Quizartinib Data Move FLT3 Inhibition Forward in AML Paradigm
FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.
Source: OncLive